Common Contracts
26 similar Change in Control and Severance Agreement contracts by Athira Pharma, Inc., ARYA Sciences Acquisition Corp III, Kinnate Biopharma Inc., others
ATHIRA PHARMA, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • August 9th, 2024 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Javier San Martin (“Executive”), effective as of April 15, 2024 (the “Effective Date”).
IBOTTA, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 22nd, 2024 • Ibotta, Inc. • Services-advertising • Colorado
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Ibotta, Inc., a Delaware corporation (the “Company”), and Sunit Patel (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
PAYMENTUS HOLDINGS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • May 8th, 2023 • Paymentus Holdings, Inc. • Services-business services, nec • Delaware
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Paymentus Holdings, Inc., a Delaware corporation (the “Company”), and Andrew A. Gerber (“Executive”), effective as of February 7, 2022 (the “Effective Date”).
PAYMENTUS HOLDINGS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 6th, 2023 • Paymentus Holdings, Inc. • Services-business services, nec • Delaware
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Paymentus Holdings, Inc., a Delaware corporation (the “Company”), and Sanjay Kalra (“Executive”), effective as of March 6, 2023 (the “Effective Date”).
PAYMENTUS HOLDINGS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • February 14th, 2023 • Paymentus Holdings, Inc. • Services-business services, nec • Delaware
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Paymentus Holdings, Inc., a Delaware corporation (the “Company”), and Paul Seamon (“Executive”), effective as of February 14, 2023 (the “Effective Date”).
RenovoRX, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 19th, 2022 • RenovoRx, Inc. • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between RenovoRx, Inc., a Delaware corporation (the “Company”), and Angela Gill Nelms (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
NAUTILUS BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • August 2nd, 2022 • Nautilus Biotechnology, Inc. • Laboratory analytical instruments • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Nautilus Biotechnology Inc., a Delaware corporation (the “Company”), and Mary Godwin (“Executive”), effective as of the date this Agreement is executed by both the Company and Executive (the “Effective Date”).
NAUTILUS BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • May 3rd, 2022 • Nautilus Biotechnology, Inc. • Laboratory analytical instruments • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Nautilus Biotechnology Inc., a Delaware corporation (the “Company”), and Gwen Weld (“Executive”), effective as of the date this Agreement is executed by both the Company and Executive (the “Effective Date”).
ATHIRA PHARMA, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 28th, 2022 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Kevin Church (“Executive”), effective as of January 31, 2022 (the “Effective Date”).
PAYMENTUS HOLDINGS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 3rd, 2022 • Paymentus Holdings, Inc. • Services-business services, nec • Delaware
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Paymentus Holdings, Inc., a Delaware corporation (the “Company”), and Gerasimos (Jerry) Portocalis (“Executive”), effective as of February 7, 2022 (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • August 16th, 2021 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Rachel Lenington (“Executive”), effective as of June 14, 2021 (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • August 16th, 2021 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Mark Worthington (“Executive”), effective as of June 1, 2021 (the “Effective Date”).
KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • June 7th, 2021 • Kinnate Biopharma Inc. • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Neha Krishnamohan (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
NAUTILUS BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • April 26th, 2021 • ARYA Sciences Acquisition Corp III • Blank checks • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Nautilus Biotechnology Inc., a Delaware corporation (the “Company”), and Parag Mallick (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
NAUTILUS BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • April 26th, 2021 • ARYA Sciences Acquisition Corp III • Blank checks • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Nautilus Biotechnology Inc., a Delaware corporation (the “Company”), and Sujal Patel (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
NAUTILUS BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • April 26th, 2021 • ARYA Sciences Acquisition Corp III • Blank checks • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Nautilus Biotechnology Inc., a Delaware corporation (the “Company”), and Nick Nelson (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
NAUTILUS BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • April 26th, 2021 • ARYA Sciences Acquisition Corp III • Blank checks • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Nautilus Biotechnology Inc., a Delaware corporation (the “Company”), and Subra Sankar (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
NAUTILUS BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • April 26th, 2021 • ARYA Sciences Acquisition Corp III • Blank checks • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Nautilus Biotechnology Inc., a Delaware corporation (the “Company”), and Anna Mowry (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
NAUTILUS BIOTECHNOLOGY, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • April 26th, 2021 • ARYA Sciences Acquisition Corp III • Blank checks • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Nautilus Biotechnology Inc., a Delaware corporation (the “Company”), and Matt Murphy (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • November 13th, 2020 • Kinnate Biopharma Inc. • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Mark Meltz (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • November 13th, 2020 • Kinnate Biopharma Inc. • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Eric Murphy (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • November 13th, 2020 • Kinnate Biopharma Inc. • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Nima Farzan (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
AKINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • November 13th, 2020 • Kinnate Biopharma Inc. • Pharmaceutical preparations • California
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Richard Williams (“Executive”), effective as of the Effective Date, as defined in Section 7 below.
CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 9th, 2020 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Glenna Mileson (“Executive”), effective as of September 8, 2020 (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 9th, 2020 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Mark Litton (“Executive”), effective as of September 8, 2020 (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 9th, 2020 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Leen Kawas (“Executive”), effective as of September 8, 2020 (the “Effective Date”).
